Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by CannaCash1746on Apr 22, 2015 4:12pm

106 Views

Post# 23654289

RE:RE:RE:RE:RE:RE:RE:RE:Who is the lucky one who got shares at 0.205 today?

     For accuracy's sake, you have the timeline of events a little jacked up.

     ATB-346 was in Phase 1 trials, not 2, and they recently released in vivo data gathered from patient blood samples involved in the phase 1 trial, not in vitro. In vivo results are much stronger than in vitro, so it's worth clarifying.

    That being said, I agree with you about this stock being worth the long gamble!

Bullboard Posts

Showcase Minerals identifies uranium and rare earth elements in Quebec